In a landmark trial that enrolled over 8000 patients, Jaiswal et al. demonstrated that CHIP-carriers face a 1.9-fold risk of coronary heart disease and a 4.0-fold increased risk of myocardial infarction (MI) compared to noncarriers. Here, STUB1 is linked to myocardial infarction.